Association between the Human Surfactant Protein-A(SP-A) Gene Locus and Chronic Obstructive Pulmonary Disease in Korean Population

한국인에서 만성폐쇄성폐질환과 인체 폐 표면 활성제 단백-A 유전자 대립형질의 상관관계

  • Na, Joo Ock (Department of Internal Medicine, Soonchunhyang University Collage of Medicine) ;
  • Oh, Myung Ho (Department of Pediatrics, Soonchunhyang University Collage of Medicine) ;
  • Choi, Jae Sung (Department of Internal Medicine, Soonchunhyang University Collage of Medicine) ;
  • Seo, Ki Hyun (Department of Internal Medicine, Soonchunhyang University Collage of Medicine) ;
  • Kim, Yong Hoon (Department of Internal Medicine, Soonchunhyang University Collage of Medicine)
  • 나주옥 (순천향대학교 의과대학 내과학교실) ;
  • 오명호 (순천향대학교 의과대학 소아과학교실) ;
  • 최재성 (순천향대학교 의과대학 내과학교실) ;
  • 서기현 (순천향대학교 의과대학 내과학교실) ;
  • 김용훈 (순천향대학교 의과대학 내과학교실)
  • Received : 2006.04.18
  • Accepted : 2006.06.16
  • Published : 2006.06.30

Abstract

Backgrounds: This study investigated whether or not a polymorphism in the gene encoding the surfactant protein A(SP-A) has any bearing on the individual susceptibility to the development of chronic obstructive pulmonary disease(COPD) in a genetically homogenous Korean population. Methods: The genotypes of 19 COPD patients and 20 healthy neonates as controls were tested using a polymerase chain reaction followed by restriction fragment length polymorphism analysis for the SP-A gene. Results: The specific frequencies of the 6A2 and 6A18 alleles of SP-A1 and the 1A2 allele of SP-A2 were much higher in the COPD group than control group (p<0.05). However, the frequencies of the 6A3 and 6A4 alleles of SP-A1 and the 1A0 allele of SP-A2 in the COPD group were significantly lower than the control group. In the COPD group, the frequencies of the +50 locus genotypes GG of SP-A1 and the +9 locus genotypes CC of SP-A2 were 85.0% and 60.6%, respectively, and 19.7% and 24.8% in the control group, respectively. The frequencies of the polymorphic genotypes or alleles showed a statistically significant difference between the COPD group and the control group (P<0.05). Conclusion: A genetic polymorphism in SP-A is associated with the development of COPD in the Korean population.

연구배경: 만성 폐쇄성폐 질환(이하 COPD)은 기도의 만성적인 염증이 특징인 질환이다. COPD의 발생에는 흡연 외에도 환경적, 유전적인 인자가 복합적으로 작용 한다. 폐 표면 활성제 단백-A(이하 SP-A)는 급성기 반응물질(acute phase reactant molecule)과 유사한 구조 및 기능을 가진 것으로 연구되어져 폐의 숙주방어와 염증반응에 중요하게 관여하는 것으로 알려졌다. 이에 저자들은 폐에서 염증 반응 및 면역에 관여하는 SP-A와 COPD군과의 유전자 대립형질을 비교분석하여 SP-A가 COPD의 병인에 관여하는 지를 밝히고자 본 연구를 시행하였다. 방 법: 2004년 10월부터 2004년 12월까지 순천향대학교 천안병원 호흡기 내과에서 COPD로 진단되어 치료 받고 있는 환자 19명과, 순천향대학교 천안병원 신생아실에 입원한 정상 신생아 20명을 대조군으로 하여 PCR-cRFLP 방법을 사용하여 아미노산 염기 서열의 차이에 의해 SP-A의 유전자형을 연구 하였다. 결 과: 1) COPD군의 SP-A1 유전자 대립형질은 대조군에 비해 $6A^2$$6A^{18}$ 이 통계적으로 유의하게 높은 빈도를 보였고, $6A^3$, $6A^4$는 낮은 빈도를 보였다. 2) COPD군의 SA-A2 유전자 대립형질 중 $1A^0$ 는 대조군에 비해 통계적으로 낮은 빈도를 보였고, $1A^2$는 대조군에 비해 유의하게 높은 빈도를 보였다. 3) SP-A1의 50번째 nucleotide가 GG인 경우 COPD군에서 통계적으로 의미 있게 높았고, SP-A2의 9번째 nucleotide가 CC인 경우 COPD군에서 통계적으로 의미 있게 높았다. 결 론: 우리나라에서는 SP-A의 특정 대립형질(inducer : $6A^2$, $6A^{18}$, $1A^2$ & protector : $6A^3$, $6A^4$,$1A^0$) 에 차이를 보이는 경우 COPD가 발생될 가능성이 높은 것을 알 수 있었고, 특히 SP-A1의 50번째 염기서열이 GG인 경우와, SP-A2의 9번째 염기서열이 CC인 경우에 COPD 발생 가능성이 높을 것으로 예측된다.

Keywords

References

  1. ATS Statement. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease: definitions, epidemiology, pathophysiology, diagnosis, and staging. Am J Respir Crit Care Med 1995;152:S77-121
  2. Bascom R. Differential susceptability to tobacco smoke: possible mechanisms. Pharmacogenetics 1991;1:102-6 https://doi.org/10.1097/00008571-199111000-00008
  3. Grese M. Pulmonary surfactant in health and human lung diseases: state of the art. Eur Respir J 1999;13:1455-76 https://doi.org/10.1183/09031936.99.13614779
  4. Behera D, Balamugesh T, Venkateswarlu D, Gupta A, Majumdar S. Serum surfactant protein-A levels in chronic bronchitis and its relation to smoking. Indian J Chest Dis Allied Sci 2005;47:13-7
  5. Wirtz H, Habscheid W, Ertl G, Schmidt M, Kochsiek K. Exogenous surfactant application in respiratory failure due to chronic obstructive pulmonary disease. Respiration 1995;62:157-9 https://doi.org/10.1159/000196413
  6. Otto-Verberne CJ, Ten Have-Opbroek AA, Franken C, Hermans J, Dijkman JH. Protective effect of pulmonary surfactant on elastase-induced emphysema in mice. Eur Respir J 1992;5:1223-30
  7. Lusuardi M, Capelli A, Carli S, Tacconi MT, Salmona M, Donner CF. Role of surfactant in chronic obstructive pulmonary disease: therapeutic implications. Respiration 1992;59(Suppl):28-32
  8. Fujishima T, Takahashi H, Abe S. Cytokines and surfactant as a factor of onset and progression of COPD. Nippon Rinsho 1999;57:1976-81
  9. Xie JG, Xu YJ, Zhang ZX, Ni W, Chen SX. Surfactant protein A gene polymorphisms in chronic obstructive pulmonary disease. Zhonghua Yi Xue Yi Chuan Xue Za Zhi 2005;22:91-3
  10. Seifart C, Plagens A, Brodje D, Muller B, von Wichert P, Floros J. Surfactant protein B intron 4 variation in German patients with COPD and acute respiratory failure. Dis Markers 2002;18:129-36 https://doi.org/10.1155/2002/194075
  11. Guo X, Lin HM, Lin Z, Montano M, Sansores R, Wang G, et al. Surfactant protein gene A, B, and D marker alleles in chronic obstructive pulmonary disease of a Mexican population. Eur Respir J 2001;18:482-90 https://doi.org/10.1183/09031936.01.00043401
  12. Guo X, Lin HM, Lin Z, Montano M, Sansores R, Wang G, et al. Polymorphisms of surfactant protein gene A, B, D, and of SP-B-linked microsatellite markers in COPD of a Mexican population. Chest 2000;117(5 Suppl 1):249S-50S https://doi.org/10.1378/chest.117.5_suppl_1.249S
  13. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease: NHLBI/WHO workshop report. No. 2701. Bethesda, National Heart, Lung and Blood Institute. NIH Publication, 2001. p. 1–.100
  14. DiAngelo S, Lin Z, Wang G, Philips S, Ramet M, Luo J, et al. Novel, Non-radioactive, simple and multiplex PCR-cRFLP methods for genotyping human SP-A and SP-D marker alleles. Dis Markers 1999;15:269-81 https://doi.org/10.1155/1999/961430
  15. Kim DS, Kim YS, Jung KS, Chang JH, Lim CM, Lee JH, et al. Prevalence of chronic obstructive pulmonary disease in Korea: a population-based spirometry survey. Am J Respir Crit Care Med 2005;172:842-7 https://doi.org/10.1164/rccm.200502-259OC
  16. Bascom R. Differential susceptibility to tobacco smoke: possible mechanism. Pharmacogenetics 1991;1:102-6 https://doi.org/10.1097/00008571-199111000-00008
  17. Wirtz H, Habscheid W, Ertl G, Schmidt M, Kochsiek K. Exogenous surfactant application in respiratory failure due to chronic obstructive pulmonary disease. Respiration 1995;62:157-9 https://doi.org/10.1159/000196413
  18. Lee KS, Kim YH, Suk JS, Ko JH, OH MH, Baw CW. Allele distribution and frequency of human surfactant protein-AI in Korean neonates. J. Korean Pediatr Soc 2002;45:1797-502
  19. Kim NC, Yoon HC, Suk JS, Ko JH, Yoo OJ, Lee IK, Oh MH, Bae CW, Allele distribution and freguency of human surfactant protein-Azin Korean neonates, J. Korean Pediatr Soc. 2003;46:340-4